FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely cardiology, and is intended for the treatment of hypertension, while it includes the SGLT-2 inhibitor and an angiotensin receptor blocker, where the SGLT-2 inhibitor is dapagliflozin or its pharmacologically acceptable salt or solvate and where the angiotensin receptor blocker is olmesartan or its pharmacologically acceptable salt or its pharmacologically acceptable ester; and where the mass ratio of olmesartan or its pharmacologically acceptable salt or its pharmacologically acceptable ester and dapagliflozin or its pharmaceutically acceptable salt or solvate is 1:0.25, 1:0.5 or 1:1.5.
EFFECT: improving the effect of lowering blood pressure and patient compliance.
4 cl, 5 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT FOR TREATMENT OF HYPERTENSION OR HIGH BLOOD PRESSURE | 2010 |
|
RU2539382C2 |
| USING HYALURONIDASE FOR PREVENTING OR TREATING ARTERIAL HYPERTENSION OR CARDIAC FAILURE | 2009 |
|
RU2508124C2 |
| COMPOSITION CONTAINING FIXED DOSE OF ANGIOTENSIN-TRANSFORMING ENZYME AND CALCIUM CANAL ANTAGONIST AND METHOD FOR PRODUCING THE COMPOSITION AND TREATING CARDIOVASCULAR DISEASES | 1998 |
|
RU2182002C2 |
| APPLICATION OF ORGANIC COMPOUNDS | 2005 |
|
RU2426532C2 |
| COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
| COMBINATION OF ORGANIC COMPOUNDS | 2003 |
|
RU2324482C2 |
| COMPOSITION FOR TREATMENT OF HYPERTENSION AND/OR FIBROSIS | 2014 |
|
RU2635564C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SELECTIVE AGONIST OF IMIDAZOLINE RECEPTOR I1 AND BLOCKER OF ANGIOTENSIN II RECEPTOR | 2004 |
|
RU2362561C2 |
| METHODS FOR SGLT2 INHIBITOR OBTAINING AND APPLICATION | 2013 |
|
RU2643764C2 |
